Increased lithium levels in water could increase the risk of autism.

Published Date: 05 Apr 2023

A new study led by a UCLA Health researcher found that pregnant women had a slightly increased risk of having children with autism spectrum disorder if the household tap water had higher lithium levels.

Read Full News

Latest News

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Episode 177: Previewing the 2026 NEALS Annual Meeting Marco Meglio, Jinsy A. Andrews, MD, MSc, Nicholas Maragakis, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus Marco Meglio

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

TSHA-102 Produces Multidomain Functional Gains in Rett Syndrome Matt Hoffman

All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

Todays Updates

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

CHEST 2026: Day 1 Recap — 5 Headlines to Know

CHEST 2026: Day 1 Recap — 5 Headlines to Know

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

Todays Updates

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

CHEST 2026: Day 1 Recap — 5 Headlines to Know

CHEST 2026: Day 1 Recap — 5 Headlines to Know

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

Latest News

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

News All Time

NeurologyLive® Brain Games: October 11, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure Marco Meglio

Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

FDA Action Update, September 2026: Approvals, Clearances, and Priority Review Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease Marco Meglio

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease Louie Pasculli

New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.

Metabolic Agent Vutiglabridin Improves Motor Scores in Early-Stage Study of Parkinson Disease Marco Meglio

Phase 2a trial results showed 800 mg vutiglabridin significantly improved motor symptom scores compared with placebo in early-stage Parkinson's disease.

New Study Reveals Plasma Biomarkers Highlight Distinct Biological Responses to Lecanemab in Alzheimer Disease Louie Pasculli, Carlos Cruchaga, PhD

Carlos Cruchaga, PhD, director of the NeuroGenomics and Informatics Center at Washington University, discusses emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.

Christen Kutz, PhD, PA-C, on What Real-World Data Reveal About Treatment Transitions to Nipocalimab in Generalized Myasthenia Gravis Marco Meglio, Christen Kutz, PhD, PA-C

Christen Kutz, PhD, PA-C, discusses a retrospective survey of neurology providers examining why patients with generalized myasthenia gravis are transitioning to nipocalimab and what real-world outcomes data suggest about its role in the treatment landscape.

Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient Hubert Fernandez, MD, Louie Pasculli

An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.

Brain Chat: The Overlap Years: Perimenopause, Menopause, and MS Mitzi Joi Williams, MD

Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of communication between patients and their health care teams, including navigating medical language, promoting shared decision-making, and advocating for clear, patient-centered care.

12-Month Gluten-Free Diet Linked to Cognitive, Quality-of-Life Improvements in Parkinson Disease Louie Pasculli

Late-breaking findings from MDS 2026 suggest a gluten-free diet may affect cognitive and quality-of-life measures in Parkinson disease, although no significant changes in motor function were observed.

Emerging Advances in Parkinson Disease Ahead of MDS 2026: Benjamin Walter, MD, MBA Benjamin L. Walter, MD, Louie Pasculli

Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.

From Cord Blood to Cannabinoids: 7 Agents to Watch in Cerebral Palsy Marco Meglio

Seven investigational cerebral palsy therapies—from baby-tooth stem cells to cannabinoids and botulinum toxin—show mixed early results, highlighting key clinical trial milestones ahead.

GLP-1/GIP Agonist KP405 Shows Biomarker Signal in Parkinson Disease Marco Meglio

Exploratory extracellular vesicle biomarkers suggested KP405, a brain-penetrant GLP-1/GIP agonist, engaged insulin signaling and neuroinflammation pathways in a small phase 1 study.

Recommended News For You

Gotistobart Response Rate Bests Chemo in Pretreated NSCLC

More cancer cases in areas where incarceration rates are high: Study

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

Triplet Therapy Improves Posttransplant Outcomes in Myeloma

Obesity-associated cancers may be on the rise in Puerto Rico

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

Recommended Articles For You

AI in Genomics: Decoding the Human Genome for Cancer Treatment 

Programmable Cell Therapies for Selective Removal of Dysfunctional Hematopoietic Cell Populations 

Amivantamab Plus Chemotherapy Outperforms Standard Care in Post-Osimertinib NSCLC 

Unlocking the Mysteries of Rhabdomyoma: A New Hope for Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

2.

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

3.

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

4.

The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.

5.

Long-Acting Interferon Therapy Approved for ET

1.

Molecular Network Mapping in Hematologic Disease

2.

Metabolic Reprogramming of the Tumor Microenvironment: Mechanisms, Clinical Relevance, and Emerging Therapeutic Strategies

3.

Hematopoietic Stem Cell Clonal Dynamics Across the Lifespan

4.

Connected Hematology Laboratory Networks for Automated Cross-Institution Data Exchange

5.

Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

2.

Common side effects of cancer treatment and how they are managed

3.

Clinical Excellence in Hematology

4.

Best Practices in Hematology

5.

Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot